Dermatology Approved Deal Benchmarks — US Only (2026)
Median upfront of $1.8B with total deal values reaching $5.2B in US Only territory.
Median Upfront
$1.8B
Total Deal Value
$4.5B
Royalty Range
11.6%–21.5%
Territory Multiplier
0.55x
Understanding Dermatology Deal Benchmarks at Approved
Approved Dermatology licensing deals in US Only territory command a median upfront payment of $1.8B, with values ranging from $1.4B at the low end to $2.2B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the dermatology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $3.8B to $5.2B, with a median of $4.5B. Royalty rates for dermatology assets at this stage typically fall between 11.6% and 21.5% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $1.4B | $1.8B | $2.2B |
| Total Deal Value | $3.8B | $4.5B | $5.2B |
| Royalty Rate | 11.6% | — | 21.5% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2022 | Nuvation Bio | Sun Pharma | $45M | $250M | licensing |
See All Comparable Deals
View 1 comparable Dermatology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Dermatology deals in US Only territory?
How does US Only territory affect Dermatology deal value?
What royalty rates are typical for Approved Dermatology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$20M upfront
Dermatology · Preclinical · US Only
$55M upfront
Dermatology · Phase 1 · US Only
$206M upfront
Dermatology · Phase 2 · US Only
$688M upfront
Dermatology · Phase 3 · US Only
$1.1B upfront
Oncology · Approved · US Only
$812M upfront
Neurology/CNS · Approved · US Only
$1.9B upfront
Immunology · Approved · US Only
$1.9B upfront
Metabolic/Obesity · Approved · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Dermatology Approved Deal Benchmarks — US Only (2026). Retrieved from https://solidus.ambrosiaventures.co/data/dermatology-approved-deals-us
<a href="https://solidus.ambrosiaventures.co/data/dermatology-approved-deals-us">Dermatology Approved Deal Benchmarks — US Only (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=dermatology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.